Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407237 | 0.84 | MEN1 (0.52) | RAB9AKITHRH2HRH1PRMT5 | |
| SCHEMBL12233216 | 0.84 | RAB9A (0.51) | RAB9AKITHRH2HRH1PRMT5 | |
| SCHEMBL21428418 | 0.84 | HTR1A (0.44) | HTR1ACYP1A2TDP1PRMT5WDR77 | |
| SCHEMBL13503648 | 0.83 | KIT (0.44) | RAB9AKITHRH2HRH1ALDH1A1 | |
| SCHEMBL22597880 | 0.83 | RAB9A (0.47) | RAB9AKITHRH2HRH1ALDH1A1 | |
| SCHEMBL5675565 | 0.83 | RAB9A (0.47) | RAB9AKITHRH2HRH1ALDH1A1 | |
| SCHEMBL3953558 | 0.83 | KIT (0.44) | RAB9AKITHRH2HRH1ALDH1A1 | |
| SCHEMBL3768429 | 0.82 | KMT2A (0.55) | RAB9AKITHRH2HRH1PRMT5 | |
| SCHEMBL14922331 | 0.82 | HRH2 (0.54) | RAB9AKITHRH2HRH1ALDH1A1 | |
| SCHEMBL1692682 | 0.82 | HRH2 (0.48) | RAB9AKITHRH2HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-3778571-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | Bioway, Inc. (KR) | 2021-02-17 | — | — | EP | disclosed |
| US-20200157048-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | BIOWAY., INC (KR) | 2020-05-21 | — | — | US | disclosed |
| WO-2019190177-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | 주식회사 바이오웨이 | 2019-10-03 | — | — | WO | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| WO-2007120972-A2 | METHOD TO TREAT SICKLE CELL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007092936-A9 | METHOD TO TREAT GASTRIC LESIONS | UNIV VIRGINIA (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007092936-A2 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-0104984-B1 | VINYLCARBAMIC ACID ESTERS AND THEIR PREPARATION | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-05-16 | — | — | EP | disclosed |
| EP-0104984-A2 | Vinylcarbamic acid esters and their preparation | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | RAB9A 2526/4885KIT 4274/4885HTR1A 2664/4885 |
| US-20200157048-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | PCK1, PCK2, ACACB | RAB9A 4215/4885KIT 1927/4885HTR1A 3578/4885 |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | RAB9A 1972/4885KIT 199/4885HTR1A 469/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | RAB9A 610/4885KIT 593/4885HTR1A 367/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | RAB9A 1308/4885KIT 1812/4885HTR1A 32/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | RAB9A 1546/4885KIT 306/4885HTR1A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.